Send this to a friend

Boston Scientific announces $600M purchase of Bedford prostate firm

Boston Scientific has announced its largest transaction this year: an acquisition of a Bedford prostate health firm for up to $600 million.
The transaction to purchase Augmenix includes half-a-billion dollars and up to $100 million for reaching sales-based milestones, Marlborough-based Boston Scientific said late Thursday.
Augmenix manufactures and markets the SpaceOAR System, a therapy used to reduce common side ...

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

Copyright 2017 New England Business Media